THE CHALLENGE
Access, not science, is the barrier today.
Advanced therapies are already saving lives, but in South America they remain out of reach due to their cost, limited infrastructure, and lack of centers to manufacture and administer them.
CAR-T therapies are highly effective against certain hematological cancers, yet they depend on imports and costly logistics that deepen inequality in access to life-saving treatments.
2nd line
IN LYMPHOMA B AND ACUTE LEUKEMIA
1
POINT-OF-CARE MANUFACTURING
OUR MODEL
Manufacture close to the patient and in partnership.
We produce CAR-T therapies in Uruguay and the region, reducing costs and avoiding the logistics of centralized manufacturing. We do this in partnership with public institutions and world-renowned centers of excellence, which contribute technology transfer and international quality standards.
01
Point-of-care manufacturing
Local production that brings therapy closer to those who need it and lowers geographical and economic barriers.
02
Strategic alliances
Public hospitals and international reference centers to transfer technology and ensure quality.
03
Access before profitability
A model designed to give continuity to the program and a predictable path for patients with few alternatives.
CONTACT
Let's talk.
Are you a patient, family member, healthcare institution, referral center, or investor? Write to us and we'll schedule a conversation.